Brigatinib (Alunbrig®)

Assessment Status Rapid Review complete
Drug Brigatinib
Brand Alunbrig®
Indication As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
Assessment Process
Rapid review commissioned 19/11/2018
Rapid review completed 11/12/2018
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations; June 2019